Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Trovafloxacin mesylate tablet|
|Abstract:||Compositions, especially in the form of tablets containing the polymorph II form of trovafloxacin mesylate, a lubricant, and microcrystalline cellulose (MC) as the diluent. Such compositions employing MC as a diluent exhibit good storage stability properties and dissolution.|
|Inventor(s):||Johnson; Alton D. (New York, NY), Sinko; Christopher M. (Niantic, CT)|
|Assignee:||Pfizer Inc. (New York, NY)|
Patent Claim Types:|
see list of patent claims
|Composition; Dosage form;|
Field: Not categorized
Back Citations: 6th percentile
Forward Citations: 0th percentile
|Patent Number||Expiration Date|
|6,187,341||February 14, 2005|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Israel||128051||<disabled in preview>|
|Iceland||4947||<disabled in preview>|
|Japan||H11269072||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.